Atropos Health Expands Oncology MultiModal Network in the Atropos Evidence Network with Addition of Ontada
PALO ALTO, Calif.--(BUSINESS WIRE)-- Atropos Health, a leader in transforming clinical real-world data (RWD) into personalized real-world evidence (RWE) and insights, has announced a strategic collaboration with Ontada®, a McKesson business and leader in community oncology RWD, clinical education, and point-of-care technologies. This collaboration will enhance the use cases for clinicians, researchers, and healthcare leaders to design care protocols, advance precision medicine and develop new treatments in oncology.
Atropos Health's automation tools generate evidence from a customer's own data, via the installation of GENEVA OS™ into customers' internal cloud data environment and the Atropos Evidence™ Network, the largest federated data network in healthcare with over 300 million patient records. As members run queries on the RWD in the Atropos Evidence Network, they have access to the right data for each question, evaluated by the Real-World Fitness Score®.
"The demand for high-quality data in oncology is ever present," said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. "The Atropos Evidence™ Network, which will now include Ontada's RWD, includes benefits across the entire healthcare ecosystem. For health systems, the oncology multi-modal network contains the high quality RWD necessary to generate the RWE needed for high-stakes clinical decisions. This collaboration with Ontada will help life sciences organizations accelerate the rate at which RWE insights drive decision-making for drug discovery and development and ensure they are presented and acted upon, driving innovation and ultimately improving the lives of cancer patients."
Ontada provides unique insights into the community oncology landscape, where approximately 85% of cancer patients are treated. Its proprietary database, iKnowMed®, is sourced in part from The US Oncology Network, a leading community oncology physician network. The US Oncology Network treats more than 1.4 million cancer patients annually. Ontada's RWD offers comprehensive insights throughout the patient journey and provides a unique view of community cancer care, representing data from more than 2.4 million patients across more than 80 tumor types.
"Ontada and Atropos Health are committed to accelerating evidence generation to drive better outcomes for patients with cancer," said Christine Davis, President of Ontada. "This collaboration will empower life sciences organizations by enhancing their evidence-generation capabilities and supporting more effective clinical decision-making that can help to improve patient care."
This collaboration comes on the heels of Atropos Health's recent announcement of Federated Nodal Deidentification Technology. The new technology will be added to the GENEVA OS™ platform, available to all Atropos Evidence™ Network members. Longitudinal patient records provide a more complete view of a patient journey.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Agriculture Silos & Storage Systems Market worth $6.53 billion by 2030- Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., June 5, 2025 /PRNewswire/ -- The agriculture silos & storage systems market is estimated at USD 5.09 billion in 2025 and is projected to reach USD 6.53 billion by 2030, at a CAGR of 5.1% from 2025 to 2030, according to a report published by MarketsandMarkets™. The development of effective storage facilities for food grains is crucial worldwide. The National Academy for Agricultural Sciences, India, emphasizes the need to reduce Food Loss and Waste (FLW), improve on-farm operations through technological interventions, increase the capacity of cold storage facilities and cold chain systems, promote the use of efficient storage systems such as metal silos, and enhance the transportation and availability of integrated cold chains. Browse in-depth TOC on "Agriculture Silos & Storage Systems Market" 268– Tables 51– Figures 280– Pages Download PDF Brochure: By silo type, flat bottom silos hold a significant market share in the global agriculture silos & storage systems market. Flat bottom silos offer a cost-effective solution for long-term storage, which safely protects the quality of grains for an extended period and ensures the best quality of grains are offered to end users. The flat bottom silo sizes range between 250 T and 20,000 T. As compared to the conical silo, the flat-bottom silo has a lower cost of storing. Thus, the flat bottom silo is one of the most convenient options for long-term grain storage. Flat bottom silo is used for both short-term and long-term storage of grains, oilseeds, and other granulated free-flowing materials in various regions, globally. By construction material, metal/steel holds a significant market share in the agriculture silos & storage systems market. Metal and steel are among the most widely used materials in the construction of agricultural silos due to their strength, durability, and versatility. Galvanized steel, in particular, offers excellent resistance to environmental stressors such as wind, moisture, and temperature fluctuations. Steel silos can be fabricated with precision, transported in modular parts, and assembled quickly on-site, making them ideal for both small and large-scale agricultural operations. Steel silos are extensively employed in grain and oilseed storage, especially in regions where harvest seasons are short, but yields are high. For instance, in countries like the United States, Canada, Ukraine, and Brazil, large steel silos serve as interim and long-term storage units for corn, soybeans, wheat, barley, and canola. Request Sample Pages: Based on region, Asia Pacific is estimated to be fastest-growing region in the agriculture silos & storage systems market. Asia Pacific is the fastest-growing region for agriculture silos and storage systems, driven by population growth, urbanization, and rising grain production in China, India, Japan, Australia, and New Zealand. The region's 2023 grain output reached 1.2 billion metric tons, with rice and maize dominating. Post-harvest losses, averaging 20-30%, particularly in India, necessitate modern silos to enhance food security for a population projected to hit 5.3 billion by 2030. Steel silos are preferred for their resistance to humidity, with flat bottom silos used for long-term storage and hopper silos for exports. The report profiles key players such as SUKUP MANUFACTURING CO. (US), AGI (Canada), MySilo (Turkey), Prado Silos (Spain), SYMAGA (Spain), TSC SILOS (Netherlands), Bentall Rowlands (UK), American Industries Partners (US), SRON SILO ENGINEERING CO. (China), TSC SILOS (Netherlands), Bentall Rowlands (UK), American Industries Partners (US), SRON SILO ENGINEERING CO. (China), and M.I.P Group (Belgium). Get 10% Free Customization on this Report: Browse Adjacent Reports @ Agriculture Industry Market Research Reports & Consulting Related Reports: Farm Equipment Rental Market by Equipment Type (Tractors, Harvesters, Sprayers, Balers & Other Equipment Types), Power Output (<30HP, 31-70HP, 71-130HP, 131-250HP, >250HP), Drive (Two-wheel Drive and Four-wheel Drive), Region – Global Forecast to 2025 Agriculture Robots Market by Type (Unmanned Aerial Vehicles/Drones, Milking Robots, Driverless Tractors, Automated Harvesting Systems), Farming Environment (Indoor and Outdoor), End-use Application and Region - Global Forecast to 2029 About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets Inc. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445 USA: +1-888-600-6441 Email: sales@ Insight: Visit Our Website: Source: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office (JPO). This milestone marks a significant step in strengthening the global intellectual property portfolio of the RenMice ® fully human antibody platform family. It underscores the continued advancement of Biocytogen's comprehensive global patent strategy and highlights the innovation and international recognition of the company's proprietary technologies. RenMab™ mice are a core member of Biocytogen's independently developed RenMice ® fully human antibody discovery platform family. Using Biocytogen's proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE ®) technology, the complete repertoire of murine immunoglobulin heavy chain and light chain variable region genes was precisely replaced in situ with their human counterparts. As a result, RenMab mice have the full repertoire of human antibody heavy chain VDJ and light chain VJ genes. It retains the ability to mount robust immune responses against diverse antigens, comparable to wild-type mice, and can generate fully human antibodies with native-like diversity, significantly improving the efficiency and success rate of discovering high-potential therapeutic candidates. Importantly, antibodies derived from RenMab mice require no additional humanization, effectively minimizing immunogenicity risks and streamlining the antibody drug development process. With distinct advantages in discovering fully human antibodies and TCRs with low immunogenicity, high diversity, favorable affinity, and excellent physicochemical properties, Biocytogen's RenMice platform series (RenMab™/RenLite ® /RenNano ® /RenTCR-mimic™/RenTCR™) has gained widespread recognition in the global biotech and biopharmaceutical industry. Licensing agreements have been established with 20+ companies, including Merck KGaA, Darmstadt, Germany, Janssen/ Johnson & Johnson, and BeiGene. Leveraging the RenMice platform, the RenBiologics™ program has generated over 1,000,000 fully human antibody sequences and numerous high-potential preclinical candidates against more than 1,000 therapeutic targets. As of December 31, 2024, approximately 200 agreements encompassing therapeutic antibody co-development, out-licensing, and asset transfers have been executed, highlighting the RenMice platform's strong global competitiveness and significant commercial value. With its sustained independent research and cutting-edge technological innovation capabilities, Biocytogen has been actively advancing its global patent portfolio and key technology protections for the RenMice ® platform. To date, the RenMice platform has secured patent grants in nearly 10 countries, including the U.S., China, and Japan, while nearly 40 patent applications are under examination across 15 countries and regions. With the steady progress of the global patent strategy, additional patent grants are anticipated in the near term. This strong intellectual property protection framework will continue to deliver reliable assurance to Biocytogen's partners worldwide. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® / RenTCR-mimic™ ) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit
Yahoo
3 hours ago
- Yahoo
SentinelOne Wins Best Security Company at the 2025 SC Awards Europe
Award recognises SentinelOne's pioneering approach to autonomous cybersecurity and advanced AI-powered defence. MOUNTAIN VIEW, Calif., June 05, 2025--(BUSINESS WIRE)--SentinelOne® (NYSE: S), a global leader in AI-powered security, today announced it has been named Best Security Company at the 2025 SC Awards Europe. This award highlights SentinelOne's pioneering role in redefining cybersecurity through its autonomous, AI-powered Singularity™ Platform, ensuring unmatched protection for organisations facing complex cyber threats. SentinelOne was also recognised as a finalist in the categories of Best Cloud Security Solution, Best Endpoint Security Solution, and Best Enterprise Security Solution. "We are honoured to be recognised as the Best Security Company at this year's SC Awards, reinforcing our commitment to innovation and excellence in protecting our customers," said Ric Smith, President of Product, Technology, and Operations at SentinelOne. "This recognition validates our relentless pursuit to deliver autonomous security solutions that proactively safeguard enterprises against increasingly sophisticated attacks." Pioneering AI-Powered Cybersecurity Pioneering autonomous cybersecurity since 2013, SentinelOne has revolutionized cyber threat defense. By integrating AI-powered technologies across endpoints, the cloud, and identities, SentinelOne delivers the industry's first end-to-end agentic AI platform solution, empowering enterprises to stay ahead of sophisticated attacks. This innovative solution has positioned SentinelOne as a leader in the cybersecurity industry, recognised for its ability to adapt and scale in an ever-evolving digital landscape. At the heart of SentinelOne's mission is a dedication to customer-centric innovation. The company's core values drive its relentless pursuit of delivering solutions that meet the unique needs of each customer and partner. By fostering strong partnerships and continuously evolving its offerings, SentinelOne ensures that organisations are equipped with the tools necessary to secure their digital environments effectively. The SC Awards Europe, now in their 16th year, celebrate outstanding cybersecurity innovation and leadership. Finalists are chosen by an expert panel comprising cybersecurity practitioners and SC Media's editorial leadership, underscoring the significance of SentinelOne's achievement. This recognition comes on the heels of SentinelOne being recognized as the Best Cloud Security and Best Endpoint Solution at the 2025 SC Awards US. To learn more about the award-winning solution and the transformation it is driving, click here. About CyberRisk Alliance (CRA) CyberRisk Alliance provides business intelligence that helps the cybersecurity ecosystem connect, share knowledge, accelerate careers, and make smarter and faster decisions. Through our trusted information brands, network of experts, and more than 250 innovative annual events we provide cybersecurity professionals with actionable insights and act as a powerful extension of cybersecurity marketing teams. Our brands include SC Media, the Official Cybersecurity Summits, Security Weekly, InfoSec World, Identiverse, CyberRisk Collaborative, ChannelE2E, MSSP Alert, LaunchTech Communications, TECHEXPO Top Secret and CyberRisk TV. Learn more at About SentinelOne SentinelOne is a global leader in AI-powered security. SentinelOne's Singularity™ Platform detects, prevents, and responds to cyber attacks at machine speed, empowering organizations to secure endpoints, cloud workloads, containers, identities, and mobile and network-connected devices with speed, accuracy and simplicity. Leading enterprises from Fortune 500s to Global 2000s, trust SentinelOne to secure tomorrow. To learn more, visit View source version on Contacts Regan Schiappapress@
